Samsung finalizes Raypax beta siteKorean PACS firm Samsung has announced that Palo Alto Medical Clinic has agreed to be the beta site for the company’s Raypax PACS product. The clinic will be Samsung’s first U.S. installation of Raypax
Korean PACS firm Samsung has announced that Palo Alto Medical Clinic has agreed to be the beta site for the companys Raypax PACS product. The clinic will be Samsungs first U.S. installation of Raypax since it received 510(k) clearance earlier this year (
PNN
8/99). The system was installed the first week of August, and initially will deal with two modalities, CT and MRI. Samsung, which maintains U.S. operations in San Jose, CA, will work with PAMC to create a version of Raypax that meets the requirements of American radiologists, the company said.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.